Translational Sciences, Inc.   Report issue

For profit Phase 2
Founded: Phoenix AZ United States (2015)
Status: Defunct (2017)

Organization Overview

First Clinical Trial
2015
NCT03001544
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2024

Timeline

NOW
  • Now

Alternative names

Translational Sciences, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

ts23 (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Brain Ischemia (Phase 1)

Cerebral Infarction (Phase 1)

Embolism (Phase 1)

Infarction (Phase 1)

Ischemia (Phase 1)

Myocardial Infarction (Phase 1)

Pulmonary Embolism (Phase 1)

Thrombosis (Phase 1)

Venous Thrombosis (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 1